FMP

FMP

Enter

INZY - Inozyme Pharma, Inc.

Profile of Inozyme Pharma, Inc.(INZY), Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics f

About

ceo

Dr. Douglas A. Treco Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.inozyme.com

exchange

NASDAQ

Description

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

CIK

0001693011

ISIN

US45790W1080

CUSIP

45790W108

Address

321 Summer Street

Phone

857 330 4340

Country

US

Employee

59

IPO Date

Jul 24, 2020

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep